Hospitals See Growing 340B Profits on Cancer Drugs: 4 Findings
The 340B Drug Pricing Program has driven hospitals to play a greater role in oncology care due to more favorable reimbursement, as evidenced by the fact hospital outpatient facilities saw their average profit margins on Medicare Part B hospital cancer drug reimbursement through the program grow to 49 percent in 2015, according to a study released Tuesday by the Community Oncology Alliance.
Hospitals See Growing 340B Profits on Cancer Drugs: 4 Findings
The 340B Drug Pricing Program has driven hospitals to play a greater role in oncology care due to more favorable reimbursement, as evidenced by the fact hospital outpatient facilities saw their average profit margins on Medicare Part B hospital cancer drug reimbursement through the program grow to 49 percent in 2015, according to a study released Tuesday by the Community Oncology Alliance.
